Bose H S, Sugawara T, Strauss J F, Miller W L
Department of Pediatrics, University of California at San Francisco, 94143-0978, USA.
N Engl J Med. 1996 Dec 19;335(25):1870-8. doi: 10.1056/NEJM199612193352503.
Congenital lipoid adrenal hyperplasia results in severe impairment of steroid biosynthesis in the adrenal glands and gonads that is manifested both in utero and postnatally. We recently found mutations in the gene for the steroidogenic acute regulatory protein in four patients with this syndrome, but it was not clear whether all patients have such mutations or why there is substantial clinical variation in these patients.
We directly sequenced the gene for steroidogenic acute regulatory protein in 15 patients with congenital lipoid adrenal hyperplasia from 10 countries. Identified mutations were confirmed and recreated in expression vectors, transfected into cultured cells, and assayed for the presence and activity of steroidogenic acute regulatory protein.
Fifteen different mutations in the gene for steroidogenic acute regulatory protein were found in 14 patients; the mutation Gln258Stop was found in 80 percent of affected alleles from Japanese and Korean patients, and the mutation Arg182Leu was found in 78 percent of affected alleles from Palestinian patients. We developed diagnostic tests for these and eight other mutations. Thirteen of the 15 mutations were in exons 5, 6, or 7, and all rendered the steroidogenic acute regulatory protein inactive in functional assays. Some mutants with amino acid replacements were capable of normal mitochondrial processing, indicating that the activity of steroidogenic acute regulatory protein is not associated with its translocation into mitochondria. Steroidogenic cells lacking the protein retained low levels of steroidogenesis. This explains the secretion of some steroid hormones by the ovaries after puberty before affected cells accumulate large amounts of cholesterol esters.
The congenital lipoid adrenal hyperplasia phenotype is the result of two separate events, an initial genetic loss of steroidogenesis that is dependent on steroidogenic acute regulatory protein and a subsequent loss of steroidogenesis that is independent of the protein due to cellular damage from accumulated cholesterol esters.
先天性类脂性肾上腺增生导致肾上腺和性腺中类固醇生物合成严重受损,这在子宫内和出生后均有表现。我们最近在4例该综合征患者中发现了类固醇生成急性调节蛋白基因的突变,但尚不清楚所有患者是否都有此类突变,也不清楚这些患者为何存在显著的临床差异。
我们对来自10个国家的15例先天性类脂性肾上腺增生患者的类固醇生成急性调节蛋白基因进行了直接测序。对鉴定出的突变进行确认,并在表达载体中重建,转染到培养细胞中,检测类固醇生成急性调节蛋白的存在和活性。
在14例患者中发现了类固醇生成急性调节蛋白基因的15种不同突变;在日本和韩国患者80%的受累等位基因中发现了Gln258Stop突变,在巴勒斯坦患者78%的受累等位基因中发现了Arg182Leu突变。我们针对这些突变以及其他8种突变开发了诊断测试。15种突变中的13种位于外显子5、6或7,并且在功能测定中均使类固醇生成急性调节蛋白失活。一些氨基酸替换的突变体能够进行正常的线粒体加工,表明类固醇生成急性调节蛋白的活性与其转运到线粒体无关。缺乏该蛋白的类固醇生成细胞仍保留低水平的类固醇生成。这解释了青春期后卵巢在受累细胞积累大量胆固醇酯之前仍能分泌一些类固醇激素的现象。
先天性类脂性肾上腺增生表型是两个独立事件的结果,一是依赖类固醇生成急性调节蛋白的类固醇生成的初始遗传丧失,二是由于积累的胆固醇酯导致的细胞损伤而出现的不依赖该蛋白的类固醇生成的后续丧失。